Skip to main content

Table 1 patient and tumor characteristics

From: Prognostic significance of anti-p53 and anti-KRas circulating antibodies in esophageal cancer patients treated with chemoradiotherapy

  

Missing values

n (%)

Overall population

  

84 (100)

Gender

Female

0

9 (11)

 

Male

 

75 (84)

Age (years)

< 60

0

42 (50)

 

≥ 60

 

42 (50)

Histology

ACE

0

27 (32)

 

SCCE

 

57 (68)

Karnofsky Performance status

≤ 60

1

10 (12)

 

70

 

6 (7)

 

80

 

21 (25)

 

90

 

25 (30)

 

100

 

21 (25)

Dysphagia

Solid

0

64 (76)

 

Liquid

 

20 (24)

Weight loss ≥ 10%

No

2

42 (51)

 

Yes

 

40 (49)

Hemoglobin level < 120 g/L

Yes

0

57 (68)

 

No

 

27 (32)

T Stage

1

0

3 (4)

 

2

 

10 (12)

 

3

 

59 (70)

 

4

 

12 (14)

N Stage

0

0

28 (33)

 

1

 

27 (32)

 

2

 

29 (35)

M Stage

No

0

67 (80)

 

Yes

 

17 (20)

Surgery

No

0

78 (81)

 

Yes

 

16 (19)

Chemoradiotherapy

Preoperative

0

16 (19)

 

Postoperative

 

6 (7)

 

Alone

 

62 (74)

  1. Abbreviations: SCCE, squamous cell carcinoma of the esophagus; ACE, adenocarcinoma of the esophagus